Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.

PHASE3CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
DRUG

Eltrombopag

Thrombopoietin receptor agonist

DRUG

Placebo

Placebo with no active pharmaceutical ingredient

Trial Locations (51)

333

GSK Investigational Site, Taoyuan District

704

GSK Investigational Site, Tainan City

1425

GSK Investigational Site, Capital Federal

10126

GSK Investigational Site, Turin

10330

GSK Investigational Site, Bangkok

11219

GSK Investigational Site, Brooklyn

13353

GSK Investigational Site, Berlin

20900

GSK Investigational Site, Monza

28007

GSK Investigational Site, Madrid

29011

GSK Investigational Site, Málaga

30120

GSK Investigational Site, Murcia (El Palmar)

31008

GSK Investigational Site, Pamplona

31048

GSK Investigational Site, Haifa

33701

GSK Investigational Site, St. Petersburg

40002

GSK Investigational Site, Khon Kaen

40138

GSK Investigational Site, Bologna

46026

GSK Investigational Site, Valencia

49202

GSK Investigational Site, Petah Tikva

52621

GSK Investigational Site, Ramat Gan

55131

GSK Investigational Site, Mainz

64239

GSK Investigational Site, Tel Aviv

76100

GSK Investigational Site, Rehovot

79106

GSK Investigational Site, Freiburg im Breisgau

84101

GSK Investigational Site, Beersheba

84113

GSK Investigational Site, Salt Lake City

90027

GSK Investigational Site, Los Angeles

90110

GSK Investigational Site, Songkhla

105077

GSK Investigational Site, Moscow

117198

GSK Investigational Site, Moscow

198205

GSK Investigational Site, Saint Petersburg

350007

GSK Investigational Site, Krasnodar

613 00

GSK Investigational Site, Brno

775 20

GSK Investigational Site, Olomouc

708 52

GSK Investigational Site, Ostrava

154 00

GSK Investigational Site, Prague

Unknown

GSK Investigational Site, Pokfulam

GSK Investigational Site, Shatin

GSK Investigational Site, Bydgoszcz

GSK Investigational Site, Madrid

GSK Investigational Site, Bangkok

00165

GSK Investigational Site, Rome

80-952

GSK Investigational Site, Gdansk

91-738

GSK Investigational Site, Lodz

20-093

GSK Investigational Site, Lublin

08035

GSK Investigational Site, Barcelona

B4 6NH

GSK Investigational Site, Birmingham

CF14 4XW

GSK Investigational Site, Cardiff

SW17 0QT

GSK Investigational Site, London

M13 9WL

GSK Investigational Site, Manchester

RM7 0AG

GSK Investigational Site, Romford

S10 2TH

GSK Investigational Site, Sheffield

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01520909 - Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body. | Biotech Hunter | Biotech Hunter